TraceLink Inc., a North Reading, Mass.-based track and trace network for connecting the life sciences supply chain and eliminating counterfeit prescription drugs from the global marketplace, raised $51.5M in Series C financing.
The round was led by Goldman Sachs Growth Equity (GS Growth), with participation from existing Series A and Series B investors FirstMark Capital, Volition Capital, and F-Prime Capital. In conjunction with the funding, Jason Kreuziger from Goldman Sachs and Amish Jani of FirstMark Capital joined TraceLink’s Board of Directors.
The company intends to use the funds to grow in the global pharmaceutical track and trace industry.
Founded in 2009, and led by Shabbir Dahod, president and CEO, TraceLink provides the Life Sciences Cloud, a suite of SaaS track and trace applications natively integrated with Amazon Web Services to enable businesses across the pharmaceutical supply chain to comply with country-specific track and trace authentic prescription medicine requirements.
The company serves more than 450 life sciences companies worldwide.